We are live on
!
Find out more
BCA
Benchmark Capital Advisors Portfolio holdings
AUM
$101M
1-Year Est. Return
0.8%
This Fund
S&P 500
This Quarter
Est. Return
+6.65%
1 Year Est. Return
-0.8%
3 Year Est. Return
+29.53%
5 Year Est. Return
+43.22%
10 Year Est. Return
–
AUM
$132M
AUM Growth
+$5.73M
(+4.5%)
Cap. Flow
-$179K
Cap. Flow
% of AUM
-0.14%
Top 10 Holdings %
Top 10 Hldgs %
31.6%
Holding
141
New
11
Increased
30
Reduced
56
Closed
10
Avg Time Held Equity + Options
11.9
quarters
Top 10 Avg Time Held Equity + Options
7.1
quarters
Top 20 Avg Time Held Equity + Options
9.2
quarters
Avg Time Held Equity only
11.9
quarters
Top 10 Avg Time Held Equity only
7.1
quarters
Top 20 Avg Time Held Equity only
9.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$1.64M |
| 2 |
Newell Brands
NWL
|
+$1.16M |
| 3 |
Meta Platforms (Facebook)
META
|
+$1.05M |
| 4 |
Apple
AAPL
|
+$1.02M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$1,000K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$2.2M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$1.44M |
| 3 |
Viasat
VSAT
|
+$1.26M |
| 4 |
iShares Europe ETF
IEV
|
+$1.17M |
| 5 |
Novartis
NVS
|
+$1.07M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 17.42% |
| 2 | Technology | 15.72% |
| 3 | Real Estate | 14.11% |
| 4 | Healthcare | 13.29% |
| 5 | Financials | 11.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Apple
AAPL
$4.98T
| $7.03M | 5.32% |
151,964
+22,500
| +17% | +$1.02M |
2013 Q2
20 quarters
|
|
2
BK Technologies
BKTI
$272M
| $5.49M | 4.15% |
296,990
-5,905
| -2% | -$111K |
2013 Q2
20 quarters
|
|
3
KKR & Co
KKR
$82.1B
| $4.43M | 3.35% |
178,463
+7,950
| +5% | +$177K |
2014 Q2
16 quarters
|
|
4
Arbor Realty Trust
ABR
$528M
| $4.21M | 3.18% |
403,519
+14,700
| +4% | +$137K |
2013 Q2
20 quarters
|
|
5
General Motors
GM
$72.3B
| $4.12M | 3.12% |
104,593
-6,500
| -6% | -$256K |
2014 Q3
15 quarters
|
|
6
Microsoft
MSFT
$4.02T
| $3.99M | 3.02% |
40,465
-2,300
| -5% | -$223K |
2013 Q2
20 quarters
|
|
7
Pfizer
PFE
$162B
| $3.29M | 2.49% |
95,624
-7,167
| -7% | -$245K |
2013 Q2
20 quarters
|
|
8
Berkshire Hathaway Class A
BRK.A
$1.11T
| $3.1M | 2.35% |
11
| – | – |
2014 Q1
17 quarters
|
|
9
Hercules Capital
HTGC
$3.1B
| $3.06M | 2.31% |
241,717
-2,422
| -1% | -$29.9K |
2013 Q2
20 quarters
|
|
10
Medical Properties Trust
MPT
$1.88B
| $3.05M | 2.31% |
217,250
-5,300
| -2% | -$70.2K |
2015 Q2
12 quarters
|
|
|
RLH
11
DELISTED
Red Lions Hotel Corporation
RLH
| $2.72M | 2.06% |
233,297
-10,144
| -4% | -$108K |
2013 Q2
20 quarters
|
|
12
Sprott Physical Gold
PHYS
$14.9B
| $2.68M | 2.03% |
263,371
-13,100
| -5% | -$139K |
2013 Q2
20 quarters
|
|
|
AERI
13
DELISTED
Aerie Pharmaceuticals
AERI
| $2.36M | 1.79% |
35,000
+5,400
| +18% | +$302K |
2014 Q3
15 quarters
|
|
14
Intel
INTC
$536B
| $2.28M | 1.73% |
45,950
+700
| +2% | +$37.2K |
2017 Q4
2 quarters
|
|
|
15
Bristol-Myers Squibb
BMY
$118B
| $2.19M | 1.66% |
39,550
-40,800
| -51% | -$2.2M |
2013 Q3
19 quarters
|
|
16
Macy's
M
$6B
| $2.13M | 1.61% |
57,000
-3,000
| -5% | -$101K |
2017 Q3
3 quarters
|
|
|
17
Meta Platforms (Facebook)
META
$1.89T
| $1.87M | 1.41% |
9,625
+5,825
| +153% | +$1.05M |
2013 Q3
19 quarters
|
|
18
Citigroup
C
$221B
| $1.84M | 1.39% |
27,525
-1,945
| -7% | -$134K |
2014 Q3
15 quarters
|
|
19
AT&T
T
$154B
| $1.78M | 1.34% |
73,286
+8,892
| +14% | +$223K |
2015 Q2
12 quarters
|
|
20
WisdomTree Japan Hedged Equity Fund
DXJ
$2.38B
| $1.73M | 1.31% |
96,390
-8,700
| -8% | -$164K |
2017 Q2
4 quarters
|
|
21
Chimera Investment
CIM
$733M
| $1.72M | 1.3% |
31,410
-1,667
| -5% | -$90K |
2014 Q1
17 quarters
|
|
22
Devon Energy
DVN
$53.9B
| $1.71M | 1.29% |
38,803
-1,700
| -4% | -$65.9K |
2013 Q2
20 quarters
|
|
23
DELISTED
Walgreens Boots Alliance
WBA
| $1.7M | 1.29% |
28,350
-2,100
| -7% | -$135K |
2016 Q2
8 quarters
|
|
|
24
Merck
MRK
$359B
| $1.68M | 1.27% |
+29,082
| New | +$1.64M |
2018 Q2
0 quarters
|
|
25
Mondelez International
MDLZ
$78.9B
| $1.6M | 1.21% |
39,123
-5,400
| -12% | -$217K |
2013 Q2
20 quarters
|
|
Similar funds
OIMU
7A
JCP
DCM
BCEM
QAM
CFA
BPV
Benchmark Capital Advisors's Q2 2018 Portfolio in Review
As of Q2 2018, Benchmark Capital Advisors held 141 positions worth $132M, up 4.5% from $127M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Benchmark Capital Advisors's Q2 2018 filing shows 11 new, 30 increased, 56 reduced and 10 closed positions. Its largest new stake was Merck: 29,082 shares worth $1.68M. The largest sale was Bristol-Myers Squibb, an estimated $2.2M.
By sector, the portfolio is most concentrated in Miscellaneous at 17% of assets, down from 20% a quarter earlier, followed by Technology and Real Estate.
- Benchmark Capital Advisors's largest Q2 2018 buy was Merck: 29,082 shares worth $1.68M.
- Benchmark Capital Advisors added most to Meta Platforms (Facebook) in Q2 2018, an estimated $1.05M increase.
- Benchmark Capital Advisors's biggest Q2 2018 reduction was Bristol-Myers Squibb, cutting an estimated $2.2M.
- Benchmark Capital Advisors fully exited Viasat in Q2 2018, selling an estimated $1.26M.
- Benchmark Capital Advisors's ten largest holdings make up 32% of its $132M portfolio in Q2 2018.
- Benchmark Capital Advisors opened 11 new positions and closed 10 in Q2 2018.
- Benchmark Capital Advisors's portfolio value rose 4.5% quarter-over-quarter to $132M.
Based on Benchmark Capital Advisors's 13F filing for Q2 2018, filed 25 Jul 2018.